Fresh capital follows positive Phase 2 data for ML-007C-MA as drug developers target cognition, negative symptoms and treatment adherence. Schizophrenia remains one of psychiatry’s most…
Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…
August 06, 2026
Vistagen’s Repeat-Dose Study Supports Fasedienol’s Potential in Social Anxiety Disorder
Key Points Vistagen reported topline results from an exploratory Phase 2 repeat‑dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder….
July 30, 2026
Cingulate’s Phase 3 CTx‑1301 ADHD Results Published in Leading Child & Adolescent Psychiatry Journal
Key Points Phase 3 pediatric trial results for CTx‑1301 (dexmethylphenidate) in ADHD have been published in a respected child and adolescent psychopharmacology journal, adding peer‑reviewed…
Key Points CMND‑100 has been well tolerated across several dosing groups, including higher doses, with no serious adverse events reported. An independent safety board has…
July 21, 2026
Helus Hits Full Enrollment in Phase 3 APPROACH Study for Breakthrough Depression Drug HLP003
Helus Pharma (NASDAQ: HELP) has finished enrolling patients in its Phase 3 APPROACH trial of HLP003, a key step that clears the path toward late‑stage…
AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….
Clearmind Medicine Inc. (Nasdaq: CMND) is taking a meaningful step toward turning its lead compound MEAI into a nasal spray treatment for alcohol use disorder…
Every June, the United States observes Men’s Health Month, an awareness campaign first formalized in 1994 when Congress passed legislation establishing National Men’s Health Week….
Helus Pharma, operating under Cybin (HELP), reported that enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder (MDD) is progressing as…
As National Mental Health Awareness Month draws to a close this May, Mental Health America’s 2026 theme—“More Good Days, Together”—shifts the focus from individual struggle…
April 29, 2026
Adial Pharmaceuticals Files New Patent Application To Extend AD04 Protection Toward 2045
What Adial just announced Adial Pharmaceuticals (NASDAQ: ADIL), has filed a new U.S. utility patent application for its lead drug candidate AD04. AD04 is a…